Tumor mutation burden is an imperfect predictor of response to immunotherapies. Mutations in regions of the genome unlikely to undergo loss during tumor evolution constitute a persistent tumor mutation burden that may drive sustained immunological tumor control in the context of cancer immunotherapy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Anagnostou, V. et al. Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. Sci. Trans. Med. 14, eabo3958 (2022). A comprehensive review article that discusses the development of predictive biomarkers for cancer immunotherapy.
Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Gen. 51, 202–206 (2019). This paper evaluates the context-specific association between TMB and clinical outcomes with immune checkpoint inhibition.
Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596–614.e14 (2021). This paper reports a meta-analysis of molecular determinants of response to immune checkpoint inhibition.
Anagnostou, V. et al. Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer. Cancer Discov. 7, 264–276 (2017). This paper reported loss of mutation-associated neoantigens as a mechanism of acquired resistance to immune checkpoint inhibition.
Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–581 (2014). This paper reported the role of tumor-specific mutant neoepitopes as targets of T cell responses during immune checkpoint blockade.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Niknafs, N. et al. Persistent mutation burden drives sustained anti-tumor immune responses. Nat. Med. https://doi.org/10.1038/s41591-022-02163-w (2023).
Rights and permissions
About this article
Cite this article
Persistent mutations render cancer cells susceptible to immunotherapy. Nat Med 29, 311–312 (2023). https://doi.org/10.1038/s41591-022-02175-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-02175-6
